Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue
+5.86%
EPS
−95.8%
Free cash flow
−21.4%
Total debt
−9.16%

Quarter to September 2026, against a year earlier

272.44 3.88 −1.40%
Market cap
$655.6B
P/E
41.3×
Fwd P/E
40.0×
Dividend yield
1.94%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100

Johnson & Johnson (JNJ) Book value per share

Alert me on Book value per share

Johnson & Johnson's book value per share at the end of fiscal 2025 was 33.9×, up 14.1% from 29.7× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 33.8×. Over the past ten years it has ranged from 22.3× (fiscal 2018) to 33.9× (fiscal 2025) — the current reading is the highest in ten years. Johnson & Johnson ranks 4th of 21 Drug Manufacturers General companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 33.9× 14.06%
FY2024 29.7× 9.40%
FY2023 27.1× (7.21%)
FY2022 29.3× 4.03%
FY2021 28.1× 17.01%
FY2020 24.0× 6.90%
FY2019 22.5× 0.90%
FY2018 22.3× (0.29%)
FY2017 22.3× (13.13%)
FY2016 25.7× 0.22%

Quarterly newest first

Period Book value per share Change
Sep 2026 33.8× (4.14%)
Jun 2026 35.3× 4.72%
Mar 2026 33.7× (0.49%)
Dec 2025 33.9× 2.90%
43 more quarters

Against its own ten years

Low 22.3× High 33.9×
Ten-year median 25.7×
Current reading's percentile 100

Book value per share against peers

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on JNJ